Acromegaly: Patient And Physician Perspectives

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

152 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-02

Study Completion Date

2020-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess the experiences of individuals with acromegaly who are receiving injections as part of their treatment regimen. Another objective of the study is to compare the patients' perception with their doctors' perceptions. The answers are important to help researchers and physicians understand what it is really like to take currently available treatments so that they can make efforts to improve patients' healthcare experiences, reduce treatment burden and, ultimately, improve patient's quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acromegaly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.

No interventions assigned to this group

Physicians

Physicians for those treating the patients enrolled in the study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>=18 years-old and \<95 years-old
* Patient self-reported acromegaly diagnosis which will be further confirmed by a knowledge screening based on current medications and doses
* Currently on injectable Somatostatin analogues (SSA), Sandostatin® LAR or Somatuline® Depot, for \>=12 months
* Have not had a change in dosage of their acromegaly treatment at the time of or since their last office visit
* Have seen their treating acromegaly physician within the past 12 +/-2 months NOTE: This timeframe allows two additional months for scheduling an appointment with their physician, since most patients should see their acromegaly physician at least once every 12 months
* Ability to read and understand English
* Live and receive acromegaly treatments in the US
* Willing to provide signed informed consent

Exclusion Criteria

* Previous or current participant in Mycapssa® (octreotide capsules) trial
* Use of Pegvisomant (Somavert®) monotherapy
* Use of Pasireotide (Signifor®)

Minimum Eligible Age

18 Years

Maximum Eligible Age

94 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lizheng Shi

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lizheng Shi, PhD, MsPharm

Role: PRINCIPAL_INVESTIGATOR

Tulane University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tulane School of Public Health and Tropical Medicine

New Orleans, Louisiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-879

Identifier Type: -

Identifier Source: org_study_id